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Background: Circumsporozoite protein (CSP) is essential for sporozoite formation and sporozoite invasion into
human hepatocyte. Previously, a recombinant P. vivax CSP based on chimeric repeats (rPvCSP-c) representing two
major alleles VK210 and VK247 within central region has been designed. Naturally acquired humoral immune
responses study show that antigenicity of rPvCSP-c was much higher than that of native strain. However, the
serologic reactivity of rPvCSP-c was still unclear in detail.
Methods: In present study, recognition of rPvCSP-c in vivax malaria typed VK210 and VK247 alleles was assessed.
VK210 typed and VK247 typed sera from adult residents reacted specifically with rPvCSP-c using protein array and
immunoblot assay. Additionally, anti-rPvCSP-c serum recognized the fixed VK210 and VK247 sporozoites by
immunofluorescence assay. Furthermore, statistic analysis was performed for correlational detection.
Results: The rPvCSP-c reacted with both VK210 typed and VK247 typed P. vivax infected patient sera and anti-
rPvCSP-c immune serum also reacted with VK210 and VK247 sporozoite parasites of P. vivax specifically. There was a
positive correlation between increased antibody level, age of patients and also associated with pvcsp repeat
number, although the level of responses did vary considerably in their reactivity to the rPvCSP-c from negative to
very high level within each age group.
Conclusions: These data confirmed the serologic reactivity of the novel rPvCSP-c in exposed both VK210 and
VK247 populations. These results strongly suggested that this recombinant CSP was biologically active and potently
immunogenic across major strains and raised the prospect that this protein could be used as serologic marker.Background
All species of Plasmodium shows that circumsporozoite
protein (CSP) contain a central repeat region, whose
amino acid sequence is species-specific, and its func-
tional role of the repeat sequence is recognition of
species-specific host receptors [1,2]. The repeats contain
B-cell immunodominant epitopes [3] and antibodies spe-
cific to this region can protect against malaria by
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reproduction in any medium, provided the orparticular, the central repeat region of Plasmodium
falciparum CSP, which contains an immunodominant B
cell epitope, represented the target of the first two vac-
cine trials [4,5]. The repeat region of Plasmodium berghei
CSP, alone, is unable to mediate sporozoite infectivity in
either the mosquito or the mammalian host [6].
PvCSP contains three major alleles, VK210, VK247, and
P. vivax-like including one of three types of nonapeptide
repeat units, GDRA(A/D)GQPA, ANGA(G/D)(N/D)QPG
and APGANQ(E/G)GGAA, respectively [7-11]. Both
VK210 and VK247 of which distributed widely all of the
world [12-16], although the antigenicity of VK210 and
VK247 suggested recognition of VK210 variant was higher
than recognition of VK247 [13,17,18]. Plasmodium vivax-
like CSP was detected in samples from Brazil, Madagascar,
and Indonesia [10,11,19]. However, a number of globallyLtd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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CSP, but were positive for VK210, VK247, or both [20].
In optimization of serological marker, sensitivity of anti-
gen appeared to be essential. Apical membrane antigen 1
(AMA1), merozoite surface protein 1 C-terminal (MSP-119)
and CSP have been used in Plasmodium species as sero-
logical markers [21-24]. Highly polymorphic antigens were
not an ideal choice because the prevalent morphs in the
community of interest could differ from those of the test
antigen, which leaded to underestimation of seroprevalence
rates [25]. Different prevalence of antibodies to CSP
suggested that seroprevalence might be genetically deter-
mined [26,27]. These potential limitations should be taken
into account for designing serological marker.
In a previous study, naturally acquired humoral IgG
immune response study showed that the antigenicity of
rPvCSP was higher than that of native protein [28].
However, as global serologic marker, the serologic
reactivity of rPvCSP was still unclear in detail. In present
study, human sera from patients of both VK210 and
VK247 parasites infection reacted to the conserved
chimeric rPvCSP (rPvCSP-c), and demonstrated corre-
lation with patient age and parasitaemia in responsive-
ness. Interestingly, although there was no typical
difference of responsiveness among different repeats,
here was a tendency of negative correlation between re-
peat number and serum responsiveness.
Methods
Patient samples
One hundred six VK210 typed serum samples were
obtained from patients who were confirmed positive for
vivax malaria via microscopy at local health centers
and clinics in Gyeonggi and Gangwon Provinces near
Demilitarized Zone (DMZ) of the Republic of Korea
(ROK); Korean DMZ is an approximate 250 km long
buffer zone between North and South Korea which runs
along the 38th parallel north. Being close to North
Korea, the first reemerging case was diagnosed here, and
almost high-, medium- and low-risk malarial areas were
located at least 10 km from the DMZ [29]. Eight VK247
typed serum samples were obtained from symptomatic,
smear-positive patients from Mae Sod, Thailand, where
is a town in western Thailand that shares a border with
Burma. It is notable as trade hub and for its substantial
population of Burmese migrants and refugees. Further-
more, eighty serum samples were taken from healthy
residents in Gyeonggi and Gangwon Provinces, but far
from DMZ, who confirmed negative for vivax malaria by
microscopy, and these were used as controls. To confirm
rPvCSP-c specific reactivity, twenty P. falciparum patient
serum samples from Uganda were used as control. This
study was approved by the Institutional Review Board at
Kangwon National University Hospital.Construction and expression of rPvCSP-c
The synthetic PvCSP gene was constructed as a chimera
based on the amino acid sequence of PvCSP-VK210
(Belem strain) and PvCSP-VK247 (PNG strain). The syn-
thetic CSP gene designed in the present study consisted
four parts; i) conserved N-terminal seventy one amino
acids of VK210, ii) four VK210 (Belem strain) repeat re-
gions, iii) three VK247 (PNG strain) repeat regions, and
iv) conserved C-terminal seventy amino acids of VK210.
The classical repeat in VK210, GQPAGDRAD, was
represented three times as well as KQPGDRAD once
started from conserved N-terminal. In addition, a triple
copy of the classical VK247 repeat, GANGAGNQP, was
included in the construct. This was followed by the con-
served C-terminal region and ended at amino acids
TDVC, before the additional six histidines tag. Produc-
tion of rPvCSP-c using a wheat germ cell-free (WGCF)
expression system, which using previously described
bilayer translation reaction methods [30,31]. The
rPvCSP-c was purified using a Ni-nitrilotriacetic acid
agarose column under non-denature condition (Qiagen,
Valencia, CA, USA) as described elsewhere [32].
SDS-PAGE and Western blot analysis
The rPvCSP-c was separated by SDS-PAGE under
reducing conditions. The separated proteins were trans-
ferred to 0.45 μm PVDF membranes (Millipore, Billerica,
MA, USA) in a semi-dry transfer buffer (50 mM Tris,
190 mM glycine, 3.5 mM SDS, 20% methanol) at a con-
stant 400 mA for 40 min using a semi-dry blotting
system (ATTO Corp., Tokyo, Japan). After blocking with
5% skim milk in phosphate buffed saline containing 0.2%
Tween 20 (PBS/T), mouse anti-penta His antibody
(Qiagen), P. vivax, P. falciparum or sera from healthy
individuals (1:200) diluted into PBS/T, which were col-
lected from ROK, Thailand and Uganda, and secondary
IRDye® goat anti-mouse (1:10000, PBS/T) or IRDye® goat
anti-human (1:20000, PBS/T) (LI-COR® Bioscience,
USA) were used to detect His-tagged recombinant
proteins. Data was scanned by Odyssey infrared imaging
system (LI-COR Biosciences, Nebraska, USA) and
analysed by Odyssey software (LI-COR Inc. Lincoln,
Nebraska, USA).
Immunization of mice with rPvCSP-c
Six- to eight-week-old female BALB/c mice (DBL Co.,
Seoul, ROK) were injected intraperitoneally with ~20 μg
of rPvCSP-c and PBS as negative control with Freund’s
complete adjuvant (Sigma-Aldrich, St. Louis, MO, USA).
Three mice were used per group. Booster injections were
given after three and six weeks using the same amount
of antigen with Freund’s incomplete adjuvant (Sigma-
Aldrich). Mouse blood samples were taken two weeks
after the final boost.
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Sera from 114 vivax malaria patients, 20 falciparum mal-
aria patients and 80 healthy individuals were tested
against the rPvCSP-c using protein arrays as previous re-
port [33]. Briefly, one microlitre of rPvCSP-c (6 ng/μl)
was spotted to each well of an amino-functionalized
slide and incubated for 2 h at 37°C. The arrays were
firstly blocked with 5% BSA in PBS/T for 1 h at 37°C.
Then they were probed with human serum (1:10) that
was pre-absorbed against wheat germ lysate (1:100) to
block anti-wheat germ antibodies. The arrays were incu-
bated with serum in PBS/T for 1 h at 37°C and anti-
bodies were visualized with 10 ng/μl Alexa Fluor 546
goat anti-human IgG (Invitrogen, Carlsbad, CA, USA) in
PBS/T and scanned in a fluorescence scanner (ScanArray
Express, PerkinElmer, Boston, MA, USA) [34]. Fluores-
cence intensities of array spots were quantified by the
fixed circle method using ScanArray Express software
(version 4.0, PerkinElmer). The positive cut-off value
was calculated as the mean fluorescence intensity (MFI)
value of the negative controls plus 2 SD. For the correl-
ation between the antibody reactivity against rPvCSP-c
(MFI) and parasitaemia of vivax sample, forty nine
known parasitaemia samples were used and analysed.
Mean intensity > 10,000 was seen as high intensity, and
> 0.2 seen as high parasitaemia.
Indirect immunofluorescence assay (IFA)
Sporozoites were obtained from the salivary glands of
Anopheles dirus mosquitoes approximately 17 to 21 days
after the blood meal and typed for the strain of P. vivax
(P. vivax 210 and 247 types) [35]. The phenotype of
sporozoite was defined by PCR then using RFLP analysis
specific 210 and 247 as previous description [36]. Sporo-
zoites were coated onto multi-well slides, air dried, and
fixed with ice-cool acetone. Slides were blocked with
non-fat milk diluted to 5% in PBS at 37°C for 30 min.
Anti-rPvCSP-c serum, diluted in PBS as 1: 200, was
added to the wells, and the slides were incubated in a
humidified chamber for 1 h at 37°C. Meanwhile, only
PBS immunized serum, diluted in PBS as 1:200, also was
used to develop IFA as negative control. The slides were
washed with PBS and Alexa Fluor-488-conjugated goat
anti-mouse antibody (Invitrogen), and nuclear strain
with DAPI (4’, 6-diamidino-2-phenylindole) (Invitrogen)
was added for 30 min at 37°C. The slides were mounted
in ProLong Gold antifade reagent (Invitrogen) and visu-
alized under oil immersion in a confocal scanning laser
microscope (LSM5 PASCAL; Carl Zeiss MicroImaging,
Thornwood, NY) using a Plan-Apochromat 63×/1.4 oil
differential interference contrast (DIC) objective lens.
Images were captured with LSM5 PASCAL software and
prepared for publication with Adobe Photoshop (Adobe
Systems, San Jose, CA, USA).Statistical analyses
Simple scatter-regression was used for making standard
curve by SigmaPlot (Systat Software Inc., San Jose, CA,
USA). IgG antibody response to rPvCSP-c and the cor-
relation coefficient between antibody titers and parasit-
aemia percentage were analysed using GraphPad Prism
(GraphPad Software, San Diego, CA, USA). Spearman’s
rank correlation was used to evaluate correlations be-
tween the variables. Student t-test was used to compare
the differences between the means of each group for




Highly conserved repeat sequence in central region of
pvcsp gene exists in other P. vivax parasites. VK210 and
VK247 types are two distinct forms of PvCSP, which are
different in their central repeat region, distributing all of
world. Although P. vivax-like CSP variants is one of major
alleles in Brazil, P. vivax-like CSP variants is much less
popular than VK210 and VK247 in worldwide endemic
areas. Therefore, in order to produce a recombinant P.
vivax serologic marker that encompasses the predominant
antigenic forms of the CSP observed in the different re-
gions, A chimeric CSP, including N- and C-terminal, and
truncated repeat region of VK210, and truncated repeat
region of VK247 was constructed (Figure 1A). This
rPvCSP-c is comprised of four repeat regions from VK210
and three repeat regions from VK247 (Figure 1B).
Chimeric recombinant PvCSP was expressed as a sol-
uble His-tag fusion protein of 29 kDa. This product was
an abundant soluble protein expressed by WGCF ex-
pression system, and was successfully purified by using
of Ni-sepharose column under non-denature condition
(GE Healthcare, Camarillo, CA, USA) (Figure 2A).
Reactivity of P. vivax infected serum samples to rPvCSP-c
Sera from individuals exposed to P. vivax were used to de-
termine whether the rPvCSP-c had epitopes reactive with
antibodies induced from a naturally occurring infection.
For the initial analysis, serum was collected at random
from a small number of adult patient samples of VK210
and VK247 types. Twenty-three individual serum samples
were used for these assays, including 10 sera from vivax
patients in ROK (VK210 type), 5 sera from vivax patients
in Thailand (VK247 type), four sera from falciparum
patients in Uganda and with four negative serum samples
without exposure to malaria (Figure 2B). Additionally,
anti-His antibody was developed to confirm rPvCSP-c
purity and reactivity by Western blot analysis. Each serum
sample was incubated separately against purified rPvCSP-
c that was size fractionated by SDS-PAGE and blotted
onto PVDF membrane. Plasmodium vivax-exposed
PvCSP210 type repeats: GQPAGDRAD 
PvCSP247 type repeats: GANGAGNQP 
PvCSP chimera 
MGHNVDLSKAINLNGVNFNNVDASSLGAAHVGQSASRGRGLGENPDDEEGDAKKKKDGKKAE






Figure 1 Protein structure (not drawn to scale) and amino acid sequence of the recombinant PvCSP molecule. The repeat region is
flanked by N-terminal and C-terminal conserved regions based on the VK210 sequence. The central region represents four VK210 repeats (grey)
and three VK247 repeats (black), region I and region II indicated with green and yellow respectively (A). Totally, 205 amino acids consist of this
PvCSP chimera including four VK210 repeats (gray), three VK247 repeats (dark), region I (green) and region II (yellow) (B).
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sera from the P. faciparum-exposed or unexposed donors
did not suggesting that antibody of VK210 and VK247
typed serum samples specific to rPvCSP-c.
Recognition of rPvCSP by VK210 and VK247 allelic sera
In order to analyse the prevalence of natural infection-
induced immune response, IgG reactivity in 106 VK210Figure 2 SDS-PAGE of recombinant P. vivax CSP (rPvCSP) and its imm
30 kDa and was estimated by comparison with known molecular weight s
reducing condition and electroblotted onto PVDF membrane (B). The blot
patient serum samples from ROK adults (numbered samples) or VK247 type
ms1308); P. falciparum infected patient serum from Uganda (U6, U19, U23
Neg-3 and Neg-4) as negative control. T: total translation mix; FT: flow throand 8 VK247 allelic serum samples from Thailand and
Republic of Korea, respectively. Optimal concentration
(6 ng/μl) of protein coating for amino-functionalized
slide was determined using pooled sera from healthy
samples and vivax malaria patients was shown
in the left panel of Figure 3A. A concentration-
dependent analysis method showed a correlation coeffi-
cient (R2 = 0.96) between fluorescence intensities andunoblot reacted with human sera. The size of the rPvCSP was
tandards (A). Purified rPvCSP was separated by SDS-PAGE under
was blocked and reacted with Penta-His antibody, VK210 typed
d patient serum from Thailand (ks580, ms992, ms999, ms1231 and
and U34) and sera from vivax naïve individuals in ROK (Neg-1, Neg-2,
ugh; E: elusion; M: molecular mass marker.
Conc. ng/ µl





















Figure 3 Development of a protein array platform for profiling antibody responses to P. vivax infection. (A) Left panel. Different
concentrations of rPvCSP were probed with pooled human serum (left duplicate, negative serum; right duplicate, positive serum). Right panel.
rPvCSP (6 ng/μl) reacted with individual serum samples in duplicates. Left phase of slide: vivax negative serum samples; Right phase of two slides:
vivax positive serum samples. Red bar, pooled positive sera reacted with rPvCSP; Green bar, pooled vivax negative sera reacted with rPvCSP;
Yellow bar, 10 OD wheat germ extract reacted with rPvCSP. NM: negative P. vivax patient sera mixture; PM: positive P. vivax patient sera mixture;
N: individual negative serum; P: individual positive serum. (B) Correlation between spot intensities and the concentration of rPvCSP.
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protein arrays for antibody profiling was evaluated using
purified rPvCSP-c (Figure 3A, right panel). A range of
titers were observed, in which P. vivax infected patient
samples were significantly higher than that of falciparum
patient serum samples (p < 0.001) and vivax negative
serum samples (p < 0.0001), although there was still an
apparent cross-reactivity with P. falciparum which might
be because of conserved regions of CSP in Plasmodium
species (Figure 4A) [37].
Protein arrays detected P. vivax in 83 of 114 sera sam-
ples from the microscopically positive samples, thus,
sensitivity was 72.8%, among these protein arrays
detected positive samples, 75 of 106 VK210 sera samples
(70.8%) and 8 of 8 VK247 sera samples (100.0%)
(Table 1). From the eighty sera samples from healthy
subjects, three false positives were obtained by protein
arrays, thus, specificity was 96.2%. There was significant
difference between the fluorescent intensity of vivaxpatient serum samples and healthy serum samples re-
sponse to rPvCSP-c (p < 0.0001) (Table 1). To better de-
termine the serological responses to rPvCSP-c, whether
106 VK201 patient ages correlate with response were ex-
amined. When the subjects were divided into age groups
(< 20, 20 – < 40, ≥ 40 years or < 25, 25 – < 50, ≥ 50 years)
significant differences were seen in serologic responses
to rPvCSP-c (Table 2). There was a wide range in pa-
tients’ responsiveness to the rPvCSP-c antigen that had
a positive correlation with age (p < 0.05). The level of
antibody seen by the average and median responses in-
creased dramatically with age as expected. These results
indicated that rPvCSP was highly antigenic and was rec-
ognized by sporozoite-induced antibodies. This could
infer that rPvCSP might develop high prevalence of rec-
ognition in serological screening.
To investigate whether patient parasitaemia associated
with antibody titers, we would predict a direct relationship
between the vivax patient parasitaemia and the response
























































Figure 4 IgG antibody responses to recombinant PvCSP using protein microarrays. (A) Probing rCSP with sera from vivax or falciparum
malaria patients and from healthy individuals. Each circle indicates the data from individual serum analysed. The bar indicates mean value plus
standard deviations. The p value was calculated by Student’s t-test. (B) Forty nine known parasitaemia samples were analysed the correlation
between the antibody reactivity against rPvCSP and parasitaemia of vivax sample. Correlations were evaluated using Spearman’s correlation test.
Mean intensity > 10000 seen as high intensity, and > 0.2 seen as high parasitaemia.
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none of each serum sample titer (intensity) as well as para-
sitaemia tested was a tight correlation observed (r = 0.206,
p = 0.156, Figure 4B), although a general grouping of re-
sults based on the patient parasitaemia correlate to serum
intensity was noted. Nevertheless, in no sample was there
high titer processing in the high parasitaemia (Figure 4B,
top right quadrant), may indicate that, when the anti-
bodies against PvCSP did inhibit parasite growth, it wascontributing in some degree to the overall inhibition of
parasite growth. In contrast, high antibody titer of patient
samples only involved into low parasitaemia although low
antibody titer also involved into low parasitaemia.
Analysis of the correlation between immune response in
Korean VK210 and its repeat number
In present study, due to these VK247 typed samples contain
only 1 repeat region and Korean indigenous types were
Table 1 Prevalence (% positive), 95% confidence
intervals, and MFI values of IgG responses to rPvCSP-c in
sera typed VK210 and VK247 vivax malaria patients and
healthy individuals
Type group
No. of patients samples (n)
95% CI (%)b MFI
Positive Negative Total (%)a
VK210 75 31 106 (70.8) 61.5–78.6 5883
VK247 8 8 8 (100) 67.6.1–100 11198
Total 83 31 114 (72.8) 64.0–80.1 6256
Type group
No. of healthy samples (n)
95% CI (%)d MFI
Positive Negative Total (%)c
Total 3 77 80 (3.8) 89.6–98.7 989
aSensitivity: % of Positive in patient samples.
bConfidence intervals.
cSpecificity: % of Negative in healthy samples.
dDifferences in the total IgG prevalence for each antigen between vivax
patients and healthy individuals were calculated with Student’s-t test. P < 0.05
considered as statistically significant.
MFI mean fluorescence intensity.
Table 3 Seroprevalence to the rPvCSP-c in residents of
ROK (VK210), observed by three different repeat number
groupings
No. of repeat in
each group
No. of samples Fluorescence intensity
n % positive Mean ± SEa p valueb
18 7 100 19,930 ± 4,509 -
20 8 100 18,550 ± 4,173 0.82
24 5 100 14,510 ± 3,327 0.39
Total 20 100
aGroup mean antibody responses are given as log transformed antibody units.
bAnalyse p value by comparing with 18 repeats group. Values ≥ 1476 were
considered positive. Student t-test was developed to different groups,
comparing 20 repeats and 24 repeats with 18 repeats respectively. P < 0.05
was considered significant. SE standard error.
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VK210 typed samples from 106 positive samples were se-
quenced and analysed and all of their intensity were higher
than cut-off value, as a result, eight samples including 20
repeats, seven samples including 18 repeats and five samples
including 24 repeats within their CSP central region
(Table 3). Although there was no significant difference (p >
0.05) among three repeat groups, here is negative correlation
between repeat number and patient immune response.
Assessment of biological activity of antibodies induced
by rPvCSP-c
To assess whether antibodies generated against this
chimeric molecule were able to recognize native surface
protein of sporozoite parasites, immunofluorescenceTable 2 Seroprevalence to the rPvCSP-c in residents of
ROK (VK210), observed by two different age groupings
Age group
(years)
No. of samples Fluorescence intensity
n % positive Mean ± SEa
Group 1
< 20 17 35.3 2,483 ± 542
20 – < 40 68 76.5 6,296 ± 807b
≥ 40 21 81.0 7,299 ± 1322c
Group 2
< 25 32 46.9 4,158 ± 898
25 – < 50 58 81.0 7,182 ± 897d
≥ 50 16 81.3 6,494 ± 1466
Total 106 70.8 5,883 ± 602
aGroup mean antibody responses are given as log transformed antibody units.
Values ≥ 1476 were considered positive. Student t-test was developed to
different groups.
bp < 0.05 and c p < 0.001 compared with < 20 in group 1.
dp < 0.05 compared with < 25 in group 2.
P< 0.05 was considered significant. SE standard error.assays were performed with VK210 and VK247 sporozo-
ites of P. vivax. Sera from mice immunized with
rPvCSP-c had strong immunofluorescence reactivity
with both type of sporozoites (Figure 5) and preimmune
serum had no reactivity.
Discussion
Plasmodium vivax has two distinct forms of the CSP
designated VK210 and VK247 types, which differ in the
sequence of the central repeat region [7]. rPvCSP-c has
a truncated repeat region that incorporates the reported
variant repeat sequence combinations of VK210 and
VK247 repeat sequences. As putative serologic marker,
rPvCSP-c encompassed the predominant antigenic
forms of the CSP present in the different geographical
regions was confirmed. Plasmodium vivax-like CSP, as
another major allele, also was detected in samples from
Brazil [10,11,19]. However some further study failed to
detect this allele in global blood samples [20]. In
addition, one examination from around 1700 samples in
Thailand showed that VK210 prevalence was much
higher than that of VK247, but no P. vivax-like variant
allele detection [39]. Intriguingly, a similar strategy as
described in the original report of P. vivax-like CSP was
used to identify such allele, they were unable to detect
any variant type other than VK210 or VK247 type in P.
vivax samples from Thailand [14]. Nevertheless, all re-
peat units present in the CSP were not necessary to in-
duce effective immunity [40,41]. Therefore, in present
study, a molecule without P. vivax-like CSP region, but
diverse number of repeats of PvCSP was designed for
producing effective antigenic reactivity. As described be-
fore, the antigenicity of VK210 variant was higher that
of VK247 variant [13,17,18]. All together, rPvCSP-c
encompassed the N-terminal and C-terminal of VK210
flanking a chimeric repeat region representing VK210
and VK247, the two major alleles of PvCSP as shown in
Figure 1. This CSP-based serologic marker might be able
to target all of the field isolates with the help of adequate
Figure 5 Indirect immunofluorescence microscopy with anti-rPvCSP sera on the P. vivax sporozoites. Mouse antiserum to rPvCSP was
incubated with smears of VK210 sporozoites (VK210) and of VK247 sporozoites (VK247). In both VK210 and VK247 sporozoites, the anti-rPvCSP
serum reactivity was shown in green and nuclear staining with DAPI was shown in blue (right panels). Bright field DIC images were presented in
the left panels. Black bar indicates 5 μm.
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detection limit for P. vivax-like variant in Brazil, where
the P. vivax-like variant frequency was higher than
VK247 type frequency [10,11] and that P. vivax distribu-
tion can be different in other areas of America as
Colombia, Mexico and Asia.
In present study, thirty-one false negative and three
false positive recognitions were detected in vivax-
infected patients and healthy samples, respectively
(Table 1). Although the reason of this phenomenon was
still unclear, it was not rare that patients exposed to P.
vivax blood infection do not harvest anti-CSP antibodies
especially if the infection was caused by relapse episode
may cause the false recognitions. Recently, lower im-
munogenicity of VK247 peptide had been analysed [42],
and antibodies to VK210 were more frequent than those
to VK247 [13]. Due to the prevalence of VK247 was not
as high as VK210 type in endemic countries except lim-
ited endemic countries from previous report [43], only
few VK247 serum samples tested and the source of the
samples was limited to one geographic site in present
study, it was necessary to test more VK247 serum sam-
ples from different areas for further evaluating rPvCSP-c
serologic marker potential in future study.
Different age groupings (Table 2) show there was re-
sponse transition in those in their late 40s, leading to a
plateau in the antibody response to the rPvCSP-c. The
level of antibody response seen by the mean responses
increased significantly with age as expected because of
people repeatedly exposed to the malaria parasite [44].
These results might also demonstrate that even low level
and unstable transmission leads to a potent boosting of
the antibody level and high-level antibody only at ma-
ture adulthood in residents of this region. Antibody
levels were possibly indicative of previous exposures and
the acquisition of parasitaemia limiting blood stage in-
fection [45,46]. Previously, the vivax-infected patient
serum levels did not differ significantly between the age
groups which were different from present findings [47].
This might be because different serum samples used forresponse detection. Furthermore, this reactivity to native
protein using both VK210 and VK247 sporozoites in
an immunofluorescence assay with anti-rPvCSP-c anti-
bodies were confirmed (Figure 5). These results sug-
gested that rPvCSP-c was able to be serological marker,
reacting with the majority of vivax-infected patient
serum samples.
Since repeat region was involved B and T cells epi-
topes that different number of csp repeat of P. vivax pa-
tient serum against the chimeric protein was analysed.
Although only limited known number of repeat region
samples was shown, a negative correlation tendency
between repeat number and immune responsiveness,
which supported us a novel prospective way to design
rPvCSP-c. In Figure 4B, all higher parasitaemia samples
poorly recognized rPvCSP-c, the negative correlation be-
tween parasitaemia and rPvCSP-c, which may suggest
the antibodies against rPvCSP-c in some degree inhibit
overall parasite growth [48]. Previously, total IgG re-
sponses to PvCSP were positively with parasitaemia that
was different from present findings [47], which might be
also according to study population collected from differ-
ent geographic areas. These observations surely required
additional defined-cohort studies to address antibody
levels-protection correlations.
Previous studies show low natural immune response
against the native CSP by different geographic regions
[49,50]. Comparatively, high immune response was
analysed against synthetic peptides based on VK247 in
different parts of Columbia [17]. Furthermore, natural
immune responses in ROK to various types of PvCSP
study showed that the sensitivity of them was highly
detectable in enzyme-linked immunosorbent assays
(ELISA) [51]. These results indicated rPvCSP-c was
highly antigenic and was recognized by nature immune
response antibodies confirms previous findings that sen-
sitivity was 65% [28] (Table 1). Notably, the rPvCSP-c
sensitivity of present test was higher than that tested
using Brazilian serum samples, it might be because
rPvCSP-c backbone was VK210 that was specific for
Cheng et al. Malaria Journal 2013, 12:323
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gested that rPvCSP-c proteins expressed by cell-free ex-
pression system and evaluated by protein array were
stable. Hence, it shows the consistency of antibody level
to rPvCSP-c from natural exposure although their con-
struct is different. Together, these findings also confirm
protein array platform is easy to handle and stable for
detection immune responses instead of ELISA.
In conclusion, a soluble recombinant chimeric PvCSP
protein has been expressed and purified successfully that
includes conserved regions and variant regions of major
two types (VK210 and VK247) of the P. vivax CSP. The
specific serological reaction of rPvCSP-c to both VK210
and VK247 type vivax patient samples supported this
chimeric protein potential as global serologic marker.
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